The increasing population, the efforts to improve health worldwide and the emergence of new diseases all contribute to the mounting need for vaccines. Sanofi Pasteur is continuously investing in state-of-the-art technologies to meet this growing demand.
The geographic diversity of our production facilities is a key strength for Sanofi Pasteur. The company has major production sites in France, the United States, Argentina, Canada, China, India, Mexico and Thailand.
This diversification means an optimization of the production capacities to meet anticipated demands for current and new vaccines, through a variety of capital improvement programs.
New technologies have the potential to play an important part in this expansion.
We are investing in leading-edge manufacturing approaches, including:
- Large-scale cell culture
- Large-scale viral production
- Bacterial conjugate vaccine production
- Inactivation and detoxification technologies
- Combination vaccine production technologies